These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 29274490)

  • 1. Colchicine prodrugs and codrugs: Chemistry and bioactivities.
    Ghawanmeh AA; Chong KF; Sarkar SM; Bakar MA; Othaman R; Khalid RM
    Eur J Med Chem; 2018 Jan; 144():229-242. PubMed ID: 29274490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and biological evaluation of colchicine C-ring analogues tethered with aliphatic linkers suitable for prodrug derivatisation.
    Fournier-Dit-Chabert J; Vinader V; Santos AR; Redondo-Horcajo M; Dreneau A; Basak R; Cosentino L; Marston G; Abdel-Rahman H; Loadman PM; Shnyder SD; Díaz JF; Barasoain I; Falconer RA; Pors K
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7693-6. PubMed ID: 23103097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin.
    Bhattacharyya B; Panda D; Gupta S; Banerjee M
    Med Res Rev; 2008 Jan; 28(1):155-83. PubMed ID: 17464966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of a novel legumain-cleavable colchicine prodrug with cell-specific toxicity.
    Smith RL; Åstrand OA; Nguyen LM; Elvestrand T; Hagelin G; Solberg R; Johansen HT; Rongved P
    Bioorg Med Chem; 2014 Jul; 22(13):3309-15. PubMed ID: 24842619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationships between chemical structures and antimitotic activities of a group of colchicine alkaloids.
    Dvorácková S; Guénard D; Picot F; Simánek V; Waisser K
    Acta Univ Palacki Olomuc Fac Med; 1985; 111():13-22. PubMed ID: 2949492
    [No Abstract]   [Full Text] [Related]  

  • 6. Synthesis, Biological Evaluation, and Molecular Docking of Combretastatin and Colchicine Derivatives and their hCE1-Activated Prodrugs as Antiviral Agents.
    Richter M; Boldescu V; Graf D; Streicher F; Dimoglo A; Bartenschlager R; Klein CD
    ChemMedChem; 2019 Feb; 14(4):469-483. PubMed ID: 30605241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomes as carriers for colchicine-derived prodrugs: vascular disrupting nanomedicines with tailorable drug release kinetics.
    Crielaard BJ; van der Wal S; Le HT; Bode AT; Lammers T; Hennink WE; Schiffelers RM; Fens MH; Storm G
    Eur J Pharm Sci; 2012 Mar; 45(4):429-35. PubMed ID: 21907797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent development and SAR analysis of colchicine binding site inhibitors.
    Chen J; Liu T; Dong X; Hu Y
    Mini Rev Med Chem; 2009 Sep; 9(10):1174-90. PubMed ID: 19817710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tubulin inhibitors targeting the colchicine binding site: a perspective of privileged structures.
    Li W; Sun H; Xu S; Zhu Z; Xu J
    Future Med Chem; 2017 Oct; 9(15):1765-1794. PubMed ID: 28929799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Syntheses and biological evaluation of ring-C modified colchicine analogs.
    Yang B; Zhu ZC; Goodson HV; Miller MJ
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3831-3. PubMed ID: 20529690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of hepatocyte-specific gene expression by a targeted colchicine prodrug.
    van Rossenberg SM; Sliedregt-Bol KM; Koning G; van den Elst H; van Berkel TJ; van Boom JH; van der Marel GA; Biessen EA
    Chembiochem; 2003 Jul; 4(7):633-9. PubMed ID: 12851933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors.
    Zhang X; Kong Y; Zhang J; Su M; Zhou Y; Zang Y; Li J; Chen Y; Fang Y; Zhang X; Lu W
    Eur J Med Chem; 2015 May; 95():127-35. PubMed ID: 25805446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico design of colchicine-based bioisosteric inhibitors of tubulin for the treatment of rheumatoid arthritis.
    Wang L; Yang HJ; Tu R; Shen M; Liu D
    Mol Med Rep; 2017 Oct; 16(4):4823-4828. PubMed ID: 28849128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioreductively activatable prodrug conjugates of phenstatin designed to target tumor hypoxia.
    Winn BA; Shi Z; Carlson GJ; Wang Y; Nguyen BL; Kelly EM; Ross RD; Hamel E; Chaplin DJ; Trawick ML; Pinney KG
    Bioorg Med Chem Lett; 2017 Feb; 27(3):636-641. PubMed ID: 28007448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A polymeric colchicinoid prodrug with reduced toxicity and improved efficacy for vascular disruption in cancer therapy.
    Crielaard BJ; van der Wal S; Lammers T; Le HT; Hennink WE; Schiffelers RM; Storm G; Fens MH
    Int J Nanomedicine; 2011; 6():2697-703. PubMed ID: 22114500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular features of colchicine associated with antimitotic activity and inhibition of tubulin polymerization.
    Fitzgerald TJ
    Biochem Pharmacol; 1976 Jun; 25(12):1383-7. PubMed ID: 938560
    [No Abstract]   [Full Text] [Related]  

  • 17. Lipophilic prodrugs of a triazole-containing colchicine analogue in liposomes: biological effects on human tumor cells.
    Kuznetsova NR; Svirshchevskaya EV; Sitnikov NS; Abodo L; Sutorius H; Zapke J; Velder J; Thomopoulou P; Oschkinat H; Prokop A; Schmalz HG; Fedorov AY; Vodovozova EL
    Bioorg Khim; 2013; 39(5):609-18. PubMed ID: 25702420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combretastatin-like chalcones as inhibitors of microtubule polymerisation. Part 2: Structure-based discovery of alpha-aryl chalcones.
    Ducki S; Mackenzie G; Greedy B; Armitage S; Chabert JF; Bennett E; Nettles J; Snyder JP; Lawrence NJ
    Bioorg Med Chem; 2009 Nov; 17(22):7711-22. PubMed ID: 19837594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The tubulin colchicine domain: a molecular modeling perspective.
    Massarotti A; Coluccia A; Silvestri R; Sorba G; Brancale A
    ChemMedChem; 2012 Jan; 7(1):33-42. PubMed ID: 21990124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structures of a diverse set of colchicine binding site inhibitors in complex with tubulin provide a rationale for drug discovery.
    Wang Y; Zhang H; Gigant B; Yu Y; Wu Y; Chen X; Lai Q; Yang Z; Chen Q; Yang J
    FEBS J; 2016 Jan; 283(1):102-11. PubMed ID: 26462166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.